Overall AT use was not associated with a significant increase in TB risk compared with non-AT therapy (hazard ratio [HR] 1.2; <i>p</i> = 0.335), whereas anti-TNF biologics showed higher TB risk (HR 2.0; incidence rate [IR] 100.2 vs. 65.4 per 10<sup>5</sup> person year [PY]; <i>p</i> < 0.001). Here, TNF is linked to tuberculosis.